Molecular sensing is integral to the development of pharmaceuticals and biomaterials but is often expensive and slow. Wavesimplix is developing a patent pending optical biomaterial to simplify the detection and characterization of molecular binding events which leverages existing infrastructure to provide unique data signals, with decreased experimental troubleshooting, all within the researcher’s own lab.